Mycophenolate mofetil for hard-to-treat IgA nephropathy
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial is testing whether the drug mycophenolate mofetil can help people whose IgA nephropathy hasn't improved with standard treatments. It aims to reduce protein in the urine and protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have IgA nephropathy confirmed by a kidney biopsy.
- You have had protein in your urine (more than 1 gram per day) even after at least 6 months of standard treatments like steroids or blood pressure medications.
- Your kidney function is at least 30 mL/min (eGFR).
- You are not on dialysis and have not had a kidney transplant.
- You do not have diabetes causing kidney problems, an active infection, or significant liver disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called NM8074 for people with IgA nephropathy (a kidney disease). The medicine is given as an infusion and aims to slow down the damage to your kidneys. If you have this condition and meet the health requirements, the trial might help you manage your kidney health.
This trial tests whether hydroxychloroquine can help slow kidney damage in people with IgA nephropathy. You may qualify if you have this kidney disease, are already on two standard medicines (RAAS inhibitors and SGLT2 inhibitors), and have ongoing protein in your urine.
This study tests a new medicine called CM313 for people with IgA nephropathy, a kidney disease. The goal is to see if it can help reduce protein in the urine and protect kidney function.
This trial tests a new pill called finerenone to see if it can slow down kidney damage in people with IgA nephropathy, a type of kidney inflammation. If you qualify, you might get finerenone or a placebo, and the study will monitor your kidney health over time.
This Phase 2 study tests CM338 to see if it can help people with immunoglobulin A (IgA) nephropathy, a kidney condition. You may be able to join if you meet age, medication, and health criteria and can follow study safety rules.
This study tests an investigational drug called SCTC21C for people with IgA nephropathy, a kidney disease caused by abnormal antibodies. The drug aims to target and reduce these harmful antibodies, which may help slow kidney damage.
Hear when a new IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.